Logo_Cytuvax

CyTuVax B.V.

CyTuVax is developing vaccines against cancer and infectious disease and has developed a platform vaccination technology (specifically designed for cancer vaccination therapy) consisting of depot-attached cytokines as immune stimulator (adjuvant).

CyTuVax was founded by dr. Ren_ Vleugels and prof. Frank W. Falkenberg.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.cytuvax.com
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Oxfordlaan 556229 EV 6229
Maastricht
Netherlands
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

The distinctive feature of CyTuVax cancer vaccine is the improved maturation of dendritic cell precursors to CD86+ T-cells and transport of cytokine-micro-aggregates directly into the lymph node, which together forcefully stimulates the activation of T-cells and other immune cells.